DMPK and myotonic dystrophy type 1: Researchers at the Institute of Myology, in collaboration with teams from the University of Liège, developed a gene therapy using CRISPR interference (CRISPRi) to silence the Dmpk gene in DM1 mice, achieving over 80% of gene silencing and the correction of disease-related abnormalities [310,311].